Clinical Germline Genome Editing: When Will Good be Good Enough?

Area of Science:

• Genetics
• Reproductive Medicine
• Bioethics

Background:

• Germline genome editing necessitates rigorous clinical validation.
• Human reproduction exhibits a high failure rate, with significant miscarriage and congenital defect rates.
• Existing technologies offer potential for hereditary disease prevention.

Purpose of the Study:

• To evaluate the clinical readiness of germline genome editing.
• To contextualize the risks of genome editing against natural reproductive failures.
• To explore the potential of integrating assisted reproduction, genome editing, and sequencing for disease prevention.

Main Methods:

• Comparative analysis of reproductive failure rates and congenital disorder statistics.
• Historical review of in vitro fertilization (IVF) development and its challenges.
• Prospective assessment of technological convergence in reproductive medicine.

Main Results:

• Human reproduction has inherent high failure rates, comparable to or exceeding potential risks of early genome editing.
• Integrating assisted reproduction, genome editing, and sequencing offers a pathway to mitigate hereditary diseases.
• Historical parallels suggest research funding and regulatory hurdles may impede progress.

Conclusions:

• Clinical application of germline genome editing must be approached with realistic expectations regarding reproductive success rates.
• Technological synergy in assisted reproduction, genome editing, and sequencing holds promise for reducing the burden of genetic disorders.
• Overcoming historical research and clinical practice misalignments is crucial for advancing reproductive genetic technologies.